| Subject: | FDA Issues New Safety Warnings About Zocor |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 19 Mar 2010 - 12:00 pm |
| The U.S. Food and Drug Administration (FDA) is warning patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg. Although myopathy is a known side effect with all statins, this new warning highlights the greater risk of developing muscle injury, including rhabdomyolysis, for patients when they are prescribed and use higher doses of this drug. Rhabdomyolysis is the most serious form of myopathy... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
